Kymera Therapeutics Inc has 16 Schedule 13D or 13G filings on record since 2025-07-17. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 14.3% | 11,681,450 | SCHEDULE 13G/A, 2026-05-06 | 2026-03-31 |
| Baker Bros. Advisors LP | 10.9% | 8,676,797 | SCHEDULE 13D/A, 2025-12-11 | 2025-12-09 |
| T. Rowe Price Associates, Inc. | 10.7% | 8,873,588 | SCHEDULE 13G/A, 2026-09-08 | 2026-08-31 |
| T. Rowe Price Investment Management, Inc. | 6.7% | 5,460,257 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Biotechnology Value Fund L P | 6.3% | 2,712,852 | SCHEDULE 13D/A, 2026-06-26 | 2026-06-26 |
| BlackRock, Inc. | 5.4% | 3,803,227 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
| Wellington Management Group LLP | 4.8% | 3,889,687 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Atlas Venture Fund X, L.P. | 2.9% | 2,384,685 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Purpose of Transaction (Item 4)
Baker Bros. Advisors LP
Item 4 of Amendment No. 3 is supplemented and amended, as the case may be, as follows: The disclosure in Item 3 and in Item 6 below is incorporated herein by reference. On December 9, 2025, the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC and Wells Fargo Securities, LLC (the "Underwriters"), related to the public offering (the "Offering") of 7,000,000 shares of common stock of the Issuer ("Common Stock") at a price to the public of $86.00 per share. In addition, the Issuer granted the Underwriters an option exercisable for 30 days from the date of the Underwriting Agreement to purchase, at the public offering price less any underwriting discounts and commissions, up to an additional 1,050,000 shares of Common Stock to cover overallotments, if any ("Underwriters' Option"), which the Underwriters exercised in full on December 10, 2025. The Offering closed on December 11, 2025. Pursuant to the Offering, 667 and Life Sciences purchased 167,192 and 1,838,621 shares of Common Stock, respectively, at the offering price of $86.00 per share, totaling 2,005,813 shares of Common Stock in the aggregate. Each of 667 and Life Sciences purchased the Common Stock with their working capital. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-11; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 5.4% | SCHEDULE 13G/A |
| 2025-08-12 | Wellington Management Group LLP | 7.7% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 8.2% | SCHEDULE 13G/A |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 7.1% | SCHEDULE 13G/A |
| 2025-12-11 | Baker Bros. Advisors LP | 10.9% | SCHEDULE 13D/A |
| 2025-12-15 | Biotechnology Value Fund L P | 8.5% | SCHEDULE 13D/A |
| 2026-01-08 | Fmr LLC | 11.2% | SCHEDULE 13G/A |
| 2026-02-10 | Wellington Management Group LLP | 5.5% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 14.3% | SCHEDULE 13G/A |
| 2026-05-15 | Wellington Management Group LLP | 4.8% | SCHEDULE 13G/A |
| 2026-05-15 | T. Rowe Price Investment Management, Inc. | 6.7% | SCHEDULE 13G |
| 2026-06-26 | Biotechnology Value Fund L P | 6.3% | SCHEDULE 13D/A |
| 2026-08-13 | Atlas Venture Fund X, L.P. | 2.9% | SCHEDULE 13G/A |
| 2026-08-14 | T. Rowe Price Associates, Inc. | 8.6% | SCHEDULE 13G/A |
| 2026-09-08 | T. Rowe Price Associates, Inc. | 10.7% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Kymera Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.